NAB-paclitaxel as third-line therapy after failure of gemcitabine and 5-fluorouracil (5-FU) based combinations in advanced gall bladder cancer patients

被引：0
|
作者：
Goel, V. [1 ]
Talwar, V. [1 ]
Patnaik, N. [2 ]
Raina, S. [1 ]
Singh, S. [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Med Oncol, New Delhi, India
[2] UCMS & GTB Hosp, Pathol, Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
241P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
    Nagata, Y.
    Kinoshita, C.
    Ishimoto, U.
    Kano, T.
    Ishikawa, M.
    Mikuni, H.
    Nakatsuka, K.
    Harada, K.
    Nishimura, T.
    Noguchi, M.
    Sawada, R.
    Amano, K.
    Saruta, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis
    Matsumoto, Toshihiko
    Kimura, Shogo
    Himei, Hitomi
    Okazaki, Ukyo
    Kurioka, Yusuke
    Tsuduki, Takao
    Takagi, Shijiro
    Takatani, Masahiro
    Hiramatsu, Ysushi
    Morishita, Hirofumi
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] SALVAGE TREATMENT WITH CISPLATIN (CDDP) AND 5-FLUOROURACIL (5-FU) IN ADVANCED BREAST-CANCER PATIENTS
    PRONZATO, P
    AMOROSO, D
    BERTELLI, G
    LIONETTO, R
    ARDIZZONI, A
    CONTE, PF
    ROSSO, R
    GALLOTTI, P
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 108 - 108
  • [24] Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer: after 5-FU failure
    Schmitt, C
    Blijham, G
    Jolain, B
    Rougier, P
    Van Cutsem, E
    ANTI-CANCER DRUGS, 1999, 10 (06) : 617 - 623
  • [25] Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    E Gabriela Chiorean
    Daniel D Von Hoff
    Josep Tabernero
    Robert El-Maraghi
    Wen Wee Ma
    Michele Reni
    Marion Harris
    Robert Whorf
    Helen Liu
    Jack Shiansong Li
    Victoria Manax
    Alfredo Romano
    Brian Lu
    David Goldstein
    British Journal of Cancer, 2016, 115 : e13 - e13
  • [26] Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
    Merz, Valeria
    Cavaliere, Alessandro
    Messina, Carlo
    Salati, Massimiliano
    Zecchetto, Camilla
    Casalino, Simona
    Milella, Michele
    Caffo, Orazio
    Melisi, Davide
    CANCERS, 2020, 12 (05)
  • [27] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
  • [28] RANDOMIZED TRIAL OF MELPHALAN PLUS 5-FLUOROURACIL (5-FU) VERSUS METHYL-CCNU PLUS 5-FU IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    BERMAN, R
    GILES, GR
    MALHOTRA, A
    BIRD, GG
    GAJJAR, PD
    BUNCH, GA
    HALL, R
    CANCER TREATMENT REPORTS, 1978, 62 (03): : 457 - 459
  • [29] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [30] Metronomic therapy with 5-FU, weekly nab-paclitaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: A phase II study.
    Isacoff, William H.
    Reber, Howard A.
    Hines, Oscar J.
    Donahue, Timothy R.
    Purcell, Fay M.
    Clerkin, Barbara M.
    Clerkin, Kara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345